Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Timber Pharmaceuticals\u2019 Development Partner, AFT Pharmaceuticals, Enters into Licensing Agreement for Pascomer\u00ae (TMB-002) in Europe","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"NEW ZEALAND","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hikma Announces Exclusive Agreement with AFT Pharmaceuticals for Injectable Non-Opioid Pain Medication Combogesic\u00ae IV in the US","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"NEW ZEALAND","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"NEW ZEALAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Salus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Announces Commercial Partnership for Maxigesic IV in 9 European Countries","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"NEW ZEALAND","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Crossject","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Crossject Signs New Licensing Agreement on ZENEO\u00ae Midazolam Epilepsy Rescue Therapy with AFT Pharmaceuticals for Australia & New Zealand","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"NEW ZEALAND","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by AFT Pharmaceuticals

    Menu

    AFT Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              AFT Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag New Zealand
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Crossject Signs New Licensing Agreement on ZENEO® Midazolam Epilepsy Rescue Therapy with AFT Pharmaceuticals for Australia & New Zealand

              Details:

              Under the agreement, AFT will commercialise ZENEO® Midazolam, a combination of the single use needle-free auto injector ZENEO® and the drug product midazolam, in epileptic seizures in Australia and New Zealand.

              Lead Product(s): Midazolam

              Therapeutic Area: Neurology Product Name: Zeneo

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Crossject

              Deal Size: $0.7 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AFT Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag New Zealand
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hyloris Announces Commercial Partnership for Maxigesic IV in 9 European Countries

              Details:

              Maxigesic (paracetamol) IV is a novel, dual mode-of-action, non-opioid pain treatment delivered through intravenous (IV) infusion for use post-operatively in hospitals or when patients cannot take medicine orally.

              Lead Product(s): Paracetamol,Ibuprofen

              Therapeutic Area: Neurology Product Name: Maxigesic

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Salus Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 24, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AFT Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag New Zealand
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Quoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003

              Details:

              Under the terms of the agreement, AFT has exclusive rights to commercialize QRX003, a potential treatment for Netherton Syndrome in Australia and New Zealand, upon the receipt of regulatory approvals in both territories.

              Lead Product(s): QRX003

              Therapeutic Area: Rare Diseases and Disorders Product Name: QRX003

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Quoin Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AFT Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag New Zealand
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hikma Announces Exclusive Agreement with AFT Pharmaceuticals for Injectable Non-Opioid Pain Medication Combogesic® IV in the US

              Details:

              Hikma gets rights for the sales, marketing and distribution of Combogesic® IV in the US. Combogesic® IV is a patented intravenous formulation developed as a line extension to Maxigesic tablets, used post-operatively in hospitals when patients cannot take a medicine orally.

              Lead Product(s): Paracetamol,Ibuprofen

              Therapeutic Area: Neurology Product Name: Combogesic IV

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AFT Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag New Zealand
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Timber Pharmaceuticals’ Development Partner, AFT Pharmaceuticals, Enters into Licensing Agreement for Pascomer® (TMB-002) in Europe

              Details:

              Extension of agreement with AFT Pharmaceuticals grants Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe.

              Lead Product(s): Sirolimus

              Therapeutic Area: Dermatology Product Name: Pascomer

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Timber Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY